It has been suggested that glioblastoma cell lines with helical domain mutations are still sensitive to dual PI3Ki/MEKi treatment [9], which is consistent with our observation that the EGFR-signaling pathway is adjustable in cell line SF767. The gene discussed is EGFR; the disease is glioblastoma.